STOCK TITAN

Cellectis S.A. (CLLS) Stock News, Jan-May 2024

CLLS NASDAQ

Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.

Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.

Rhea-AI Summary

Cellectis appointed Arthur Stril as the interim Chief Financial Officer, replacing Bing Wang. Mr. Stril, with a strong background in finance and business development, will oversee finance, investor relations, and business development functions. His appointment comes at a critical growth phase for Cellectis, as they advance their pipeline of assets and explore new opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
management
-
Rhea-AI Summary

Cellectis reported financial results for the fourth quarter and full year 2023, highlighting key events like clinical study updates, strategic collaborations with AstraZeneca, and cash position. The company remains focused on advancing its Phase 1 clinical trials, presenting promising data on UCART22 and UCART20x22 at the ASH conference. The collaboration with AstraZeneca aims to develop innovative cell and gene therapies. Financially, Cellectis saw a significant increase in cash position to $156 million as of December 31, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none

FAQ

What is the current stock price of Cellectis (CLLS)?

Cellectis (CLLS) last closed at $0.9209.

What is the market cap of Cellectis (CLLS)?

The market cap of Cellectis (CLLS) is approximately $92.8M.